Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1)

被引：0
作者：
Shigeru Imoto
Kun Wang
Xi-wen Bi
Guangyu Liu
Young-Hyuck Im
Seock-Ah Im
Sung Hoon Sim
Takayuki Ueno
Manabu Futamura
Masakazu Toi
Yasuhiro Fujiwara
Sung Gwe Ahn
Jeong Eon Lee
Yeon Hee Park
Shintaro Takao
Mari Saito Oba
Yuko Kitagawa
Masahiko Nishiyama
机构：
[1] Kyorin University School of Medicine,Seoul National University Hospital
[2] Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences,Center for Breast Cancer Korea
[3] Sun Yat-Sen University Cancer Center,Breast Oncology Center
[4] Fudan University Shanghai Cancer Center,Gangnam Severance Hospital
[5] Sungkyunkwan University School of Medicine,Clinical Research and Education Promotion Division, Department of Clinical Data Science
[6] Seoul National University College of Medicine,undefined
[7] National Cancer Center,undefined
[8] Cancer Institute Hospital of the Japanese Foundation for Cancer Research,undefined
[9] Gifu University School of Medicine,undefined
[10] Kyoto University Graduate School of Medicine,undefined
[11] National Cancer Center Hospital,undefined
[12] Yonsei University College of Medicine,undefined
[13] Hyogo Cancer Center,undefined
[14] National Center of Neurology and Psychiatry,undefined
[15] Keio University Graduate School of Medicine,undefined
[16] Gunma University,undefined
来源：
Breast Cancer | 2023年 / 30卷
关键词：
Oligometastases; Locoregional therapy; Systemic therapy; Overall survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：412 / 423
页数：11
相关论文
共 158 条
  • [1] Braun S(2005)A pooled analysis of bone marrow micrometastasis in breast cancer N Engl J Med 353 793-802
  • [2] Vogl FD(2012)Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials Lancet Oncol 379 432-444
  • [3] Naume B(2015)Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials Lancet 286 1341-1352
  • [4] Janni W(2011)Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10801 women in 17 randomised trials Lancet 378 1707-1716
  • [5] Osborne MP(2009)Gene-expression signatures in breast cancer N Engl J Med 360 790-800
  • [6] Coombes RC(2015)Impact of breast cancer subtypes and patterns of metastasis on outcome Breast Cancer Res Treat 150 621-629
  • [7] Sotiriou C(2016)Palbociclib and letrozole in advanced breast cancer N Engl J Med 375 1925-1936
  • [8] Pusztai L(2020)Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study Lancet Oncol 21 519-530
  • [9] Kast K(2014)ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) Ann Oncol 25 1871-1888
  • [10] Link T(2010)International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst 102 456-463
12345678910